JP2019526537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526537A5 JP2019526537A5 JP2019503703A JP2019503703A JP2019526537A5 JP 2019526537 A5 JP2019526537 A5 JP 2019526537A5 JP 2019503703 A JP2019503703 A JP 2019503703A JP 2019503703 A JP2019503703 A JP 2019503703A JP 2019526537 A5 JP2019526537 A5 JP 2019526537A5
- Authority
- JP
- Japan
- Prior art keywords
- human insulin
- zinc complex
- acylated derivative
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 21
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 19
- 239000011701 zinc Substances 0.000 claims 18
- 229910052725 zinc Inorganic materials 0.000 claims 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 5
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004185 ester group Chemical group 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022066071A JP2022095872A (ja) | 2016-08-02 | 2022-04-13 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610625257 | 2016-08-02 | ||
| CN201610625257.5 | 2016-08-02 | ||
| CN201610779132 | 2016-08-31 | ||
| CN201610779132.8 | 2016-08-31 | ||
| PCT/CN2017/095377 WO2018024186A1 (zh) | 2016-08-02 | 2017-08-01 | 一种人胰岛素或其类似物的酰化衍生物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066071A Division JP2022095872A (ja) | 2016-08-02 | 2022-04-13 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526537A JP2019526537A (ja) | 2019-09-19 |
| JP2019526537A5 true JP2019526537A5 (enExample) | 2020-07-02 |
| JP7432361B2 JP7432361B2 (ja) | 2024-02-16 |
Family
ID=61074099
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503703A Active JP7432361B2 (ja) | 2016-08-02 | 2017-08-01 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
| JP2022066071A Pending JP2022095872A (ja) | 2016-08-02 | 2022-04-13 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022066071A Pending JP2022095872A (ja) | 2016-08-02 | 2022-04-13 | ヒトインスリンまたはそのアナログのアシル化誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10815287B2 (enExample) |
| EP (1) | EP3495384A4 (enExample) |
| JP (2) | JP7432361B2 (enExample) |
| CN (2) | CN108463468B (enExample) |
| TW (1) | TWI747929B (enExample) |
| WO (1) | WO2018024186A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3090199A1 (en) * | 2018-02-01 | 2019-08-08 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof |
| TW201934752A (zh) | 2018-02-09 | 2019-09-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種密碼子優化的人胰島素類似物前體基因和信號肽基因 |
| CA3100869A1 (en) | 2018-05-24 | 2019-11-28 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing precursor of recombinant human insulin or analogue thereof |
| SG11202106167XA (en) | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin conjugates |
| BR112022013009A2 (pt) | 2019-12-30 | 2022-09-06 | Gan & Lee Pharmaceuticals Co Ltd | Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina |
| TW202229324A (zh) * | 2020-11-27 | 2022-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 製備胰島素或其類似物的醯化衍生物的方法 |
| CN112939771A (zh) * | 2021-01-28 | 2021-06-11 | 宁夏蓝博思化学技术有限公司 | 长链烷基二酸单叔丁酯的制备方法 |
| EP4347632A4 (en) | 2021-05-24 | 2025-03-26 | Sunshine Lake Pharma Co., Ltd. | A novel acylated insulin analog |
| EP4361174A4 (en) | 2021-06-25 | 2025-11-19 | Gan & Lee Pharmaceuticals Co Ltd | ACYLATED PHARMACEUTICAL COMPOSITION CONTAINING INSULIN |
| CN118574842A (zh) | 2022-01-28 | 2024-08-30 | 甘李药业股份有限公司 | 酰化胰岛素 |
| CN117756914B (zh) * | 2023-12-15 | 2024-09-03 | 瀚晖制药有限公司 | 依柯胰岛素的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| EP1132404A3 (en) * | 1993-09-17 | 2002-03-27 | Novo Nordisk A/S | Acylated insulin |
| CN1163574A (zh) * | 1994-11-17 | 1997-10-29 | 伊莱利利公司 | 酰化的胰岛素类似物 |
| US6310038B1 (en) * | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| WO2003075950A1 (en) * | 2002-03-13 | 2003-09-18 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| EP2107069B1 (en) * | 2003-08-05 | 2013-01-16 | Novo Nordisk A/S | Novel insulin derivatives |
| ES2402592T3 (es) * | 2003-08-05 | 2013-05-07 | Novo Nordisk A/S | Nuevos derivados de insulina |
| PT1969004E (pt) * | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| CN101784563B (zh) * | 2007-08-15 | 2015-02-04 | 诺沃-诺迪斯克有限公司 | 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素 |
| EP2910571B1 (en) * | 2008-03-18 | 2016-10-05 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| US8935928B2 (en) * | 2011-10-10 | 2015-01-20 | Lockheed Martin Corporation | Integrated air-cycle refrigeration and power generation system |
| AU2012350586B2 (en) * | 2011-12-15 | 2017-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Human insulin analogue and acylated derivative thereof |
| CN106496322A (zh) * | 2015-09-07 | 2017-03-15 | 江苏恒瑞医药股份有限公司 | 人胰岛素或其类似物的酰化衍生物的制备方法 |
| KR20180105236A (ko) * | 2016-02-05 | 2018-09-27 | 메모리얼 슬로안-케터링 캔서 센터 | 줄기 세포-유래 외배엽 계통 전구체의 분화 방법 |
-
2017
- 2017-08-01 CN CN201780005001.7A patent/CN108463468B/zh active Active
- 2017-08-01 CN CN202210131921.6A patent/CN114478747B/zh active Active
- 2017-08-01 US US16/320,997 patent/US10815287B2/en active Active
- 2017-08-01 EP EP17836368.5A patent/EP3495384A4/en not_active Withdrawn
- 2017-08-01 JP JP2019503703A patent/JP7432361B2/ja active Active
- 2017-08-01 WO PCT/CN2017/095377 patent/WO2018024186A1/zh not_active Ceased
- 2017-08-01 TW TW106125882A patent/TWI747929B/zh active
-
2022
- 2022-04-13 JP JP2022066071A patent/JP2022095872A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526537A5 (enExample) | ||
| JP2022095872A5 (enExample) | ||
| JP2012512901A5 (enExample) | ||
| JP2011006428A5 (enExample) | ||
| RU99106518A (ru) | Glp-1 производные | |
| RU2008143668A (ru) | Производное инсулина | |
| WO2011080102A3 (en) | Glp-1 analogues and derivatives | |
| CA3084688A1 (fr) | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes | |
| JP2013526501A5 (enExample) | ||
| JP2015110654A5 (enExample) | ||
| RU2009122582A (ru) | Пэг-модифицированный эксендин или аналог эксендина и его композиции и применение | |
| JP2007523881A5 (enExample) | ||
| KR970042553A (ko) | 캠프토테신 유도체 | |
| EP3495384A1 (en) | Acylated derivative of human insulin or analogue thereof | |
| RU2008141280A (ru) | Агонисты рецептора нейромедина u и их применение | |
| JP2008545793A5 (enExample) | ||
| NZ599791A (en) | Therapeutic peptides | |
| RU2019109719A (ru) | Конъюгаты полимиксин-альгинатных олигомеров | |
| JP2017508741A5 (enExample) | ||
| JP2009532384A5 (enExample) | ||
| EP3740227A1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide | |
| JP5982562B2 (ja) | ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途 | |
| RU2020108281A (ru) | Новые ацилированные аналоги инсулина и варианты их применения | |
| RU2019109728A (ru) | Конъюгаты бацитрацин-альгинатный олигомер | |
| JP2013516424A (ja) | シクロスポリン類似体 |